Conference Day Two
8:25 am Chair’s Opening Remarks
Linking Model Data to Better Characterize the Tumour Microenvironment & Predict Translatability
8:30 am Effective Humanized Model Development Strategies to Empower Oncolytic Viral Therapy Research
Synopsis
- Pros and cons of huCD34+ grafted humanized CDX models
- Characterization of complex multi-parametric human tumor microenvironment
- Robustness of humanized model system to correlate the human clinical trial data
9:00 am Session Reserved for LIDE
9:30 am Leveraging in vitro & in vivo Preclinical PK/PD Data to Bridge the Translational Gap for ADC & CD3 Bispecific Clinical Development
Synopsis
- Bridging preclinical data to clinical predictions, including the use of non-clinical data for efficacious dose predictions and safety mitigations
- Strategies to empower dose predictions of an ADC and a CD3 bi-specific
- Assessing the different model data to be leveraged and understanding the opportunities and challenges with them
10:00 am Morning Break & Networking
Employing the Right Tumor Models to Empower Immunotherapy & Cell Therapy Studies & Assessing the Future
11:00 am Investigating An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Enhanced Potency & Persistence Against Multiple Oncology Indications
Synopsis
- Exploring a third generation armored allogeneic anti-CD70 CAR gamma delta T cell product
- Demonstrating rapid homing, activation and killing kinetics in preclinical models
- ADI-270 exhibited significant efficacy across multiple solid and hematological tumor models expressing various levels of CD70
11:30 am Session Reserved for GemPharmatech
12:00 pm Empowering Cell Therapy Studies by Using Better In Vivo Models
Synopsis
- Uncovering the model selection rationale for cell therapy studies
- Spotlighting key considerations such as antigen expression, TME, and pharmacokinetics in implementing relevant preclinical models
12:30 pm Lunch Break
Emerging Models & Their Applications Across Drug Development
1:30 pm Mastermind Session: Shifting from Oncology to Autoimmunity: What Cross- Learnings Could We Share When It Comes to Creating Better Models for Oncology & Autoimmune Research?
Synopsis
- Discussing the need for better preclinical models for autoimmune disease research
- How do you overcome challenges with developing these models?
- What best practices can we implement to repurpose immunotherapies and cell therapies for autoimmune disease?
2:00 pm SLE Patient PBMC Reconstituted Mouse Model for Lupus Drug Discovery & Development
Synopsis
- Sharing the case study of preclinical model development in autoimmune disease research
- Discussing opportunities and challenges for the development of humanized mouse models of SLE
- Uncovering strategies to repurpose B cell targeting immune therapies for autoimmune disorders